Wealthcare Advisory Partners LLC Decreases Stake in Pfizer Inc. $PFE

Wealthcare Advisory Partners LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.8% during the second quarter, HoldingsChannel.com reports. The firm owned 147,571 shares of the biopharmaceutical company’s stock after selling 21,711 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Pfizer were worth $3,554,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. First Bank & Trust lifted its stake in shares of Pfizer by 3.3% in the second quarter. First Bank & Trust now owns 265,755 shares of the biopharmaceutical company’s stock valued at $6,399,000 after purchasing an additional 8,373 shares during the period. Shrier Wealth Management LLC grew its position in Pfizer by 1.8% during the second quarter. Shrier Wealth Management LLC now owns 44,811 shares of the biopharmaceutical company’s stock worth $1,079,000 after buying an additional 791 shares during the period. Revolve Wealth Partners LLC grew its position in Pfizer by 9.8% during the second quarter. Revolve Wealth Partners LLC now owns 12,536 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 1,114 shares during the period. Key Client Fiduciary Advisors LLC increased its holdings in Pfizer by 7.9% in the second quarter. Key Client Fiduciary Advisors LLC now owns 31,030 shares of the biopharmaceutical company’s stock valued at $747,000 after buying an additional 2,261 shares in the last quarter. Finally, World Equity Group Inc. lifted its position in shares of Pfizer by 5.3% during the 2nd quarter. World Equity Group Inc. now owns 16,025 shares of the biopharmaceutical company’s stock valued at $386,000 after acquiring an additional 810 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PFE shares. JPMorgan Chase & Co. decreased their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Pfizer in a report on Monday, August 3rd. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Stock Down 1.6%

Shares of NYSE:PFE opened at $26.61 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The stock’s fifty day simple moving average is $25.07 and its 200-day simple moving average is $26.18. The company has a market capitalization of $151.67 billion, a P/E ratio of 35.01 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the business posted $0.78 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Raised 2026 outlook and cost savings: Pfizer increased its 2026 guidance after reporting second-quarter earnings of $0.77 per share versus the $0.68 consensus estimate and revenue of $15.03 billion versus $14.40 billion expected. Non-COVID products grew 5%, while management is targeting approximately $9.7 billion in savings, supporting profitability. Pfizer Q2 2026 Earnings Call Transcript
• Positive Sentiment: Pipeline offers a potential growth replacement: Investor coverage is highlighting Pfizer’s expanding non-COVID pipeline and strategic efforts to reduce its dependence on pandemic products. A successful pipeline could help offset upcoming revenue losses. Pfizer’s Pipeline Could Change Everything
• Neutral Sentiment: Income appeal remains significant: Pfizer’s roughly 6.4% dividend yield is well above the S&P 500 average, making PFE attractive to income-focused investors, although the high payout also reflects concerns about earnings quality and future growth. Pfizer vs AbbVie: What’s the Better Dividend Stock
• Negative Sentiment: Guidance increase may be less durable: Analysts noted that much of the improved 2026 outlook relies on a drug approaching patent expiry. That creates a potential revenue cliff from generic competition, though Pfizer says it is implementing measures to address the risk. Pfizer Raised 2026 Guidance
• Negative Sentiment: Dividend-cut concerns persist: Pfizer’s earnings have reportedly declined sharply this year, raising questions about whether its elevated dividend is sustainable if cash flow and earnings remain under pressure. Pfizer Earnings and Dividend Cut Concerns
• Negative Sentiment: Legal liability adds a financial overhang: Pfizer agreed to a $44 million settlement related to Chantix, creating a modest near-term cost and additional headline risk. Pfizer Chantix Settlement

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.